Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Cancer, Hypoxia, and Metabolism, and Peptidase Inhibition and Analysis.
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Targeting forkhead box M1 transcription factor in breast cancer
Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds
FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression
Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1
P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines
Catalytic Deoxyribozyme-Modified Nanoparticles for RNAi-Independent Gene Regulation
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion
Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance